These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 15629540)

  • 1. Effects of a behaviorally active antibody on the brain uptake and clearance of amyloid beta proteins.
    Banks WA; Pagliari P; Nakaoke R; Morley JE
    Peptides; 2005 Feb; 26(2):287-94. PubMed ID: 15629540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease.
    Bacher M; Depboylu C; Du Y; Noelker C; Oertel WH; Behr T; Henriksen G; Behe M; Dodel R
    Neurosci Lett; 2009 Jan; 449(3):240-5. PubMed ID: 18786612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody to amyloid beta protein alleviates impaired acquisition, retention, and memory processing in SAMP8 mice.
    Morley JE; Farr SA; Flood JF
    Neurobiol Learn Mem; 2002 Jul; 78(1):125-38. PubMed ID: 12071671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
    Geylis V; Steinitz M
    Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques.
    Poduslo JF; Ramakrishnan M; Holasek SS; Ramirez-Alvarado M; Kandimalla KK; Gilles EJ; Curran GL; Wengenack TM
    J Neurochem; 2007 Jul; 102(2):420-33. PubMed ID: 17596213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.
    Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Poduslo JF
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1370-8. PubMed ID: 15743932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment.
    Banks WA; Farr SA; Morley JE; Wolf KM; Geylis V; Steinitz M
    Exp Neurol; 2007 Aug; 206(2):248-56. PubMed ID: 17582399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro models for the blood-brain barrier.
    Garberg P; Ball M; Borg N; Cecchelli R; Fenart L; Hurst RD; Lindmark T; Mabondzo A; Nilsson JE; Raub TJ; Stanimirovic D; Terasaki T; Oberg JO; Osterberg T
    Toxicol In Vitro; 2005 Apr; 19(3):299-334. PubMed ID: 15713540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice.
    Sohn JH; So JO; Kim H; Nam EJ; Ha HJ; Kim YH; Mook-Jung I
    Biochem Biophys Res Commun; 2007 Sep; 361(3):800-4. PubMed ID: 17678618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
    Rakover I; Arbel M; Solomon B
    Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human monoclonal antibodies against amyloid-beta from healthy adults.
    Geylis V; Kourilov V; Meiner Z; Nennesmo I; Bogdanovic N; Steinitz M
    Neurobiol Aging; 2005 May; 26(5):597-606. PubMed ID: 15708434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain.
    Tamura Y; Hamajima K; Matsui K; Yanoma S; Narita M; Tajima N; Xin KQ; Klinman D; Okuda K
    Neurobiol Dis; 2005 Nov; 20(2):541-9. PubMed ID: 15908227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse.
    Lee HJ; Engelhardt B; Lesley J; Bickel U; Pardridge WM
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1048-52. PubMed ID: 10688622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons.
    Clifford PM; Zarrabi S; Siu G; Kinsler KJ; Kosciuk MC; Venkataraman V; D'Andrea MR; Dinsmore S; Nagele RG
    Brain Res; 2007 Apr; 1142():223-36. PubMed ID: 17306234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood-brain barrier transport of circulating Alzheimer's amyloid beta.
    Zlokovic BV; Ghiso J; Mackic JB; McComb JG; Weiss MH; Frangione B
    Biochem Biophys Res Commun; 1993 Dec; 197(3):1034-40. PubMed ID: 8280117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease.
    Wu ZL; Ciallella JR; Flood DG; O'Kane TM; Bozyczko-Coyne D; Savage MJ
    Neurobiol Aging; 2006 Mar; 27(3):377-86. PubMed ID: 15927307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-mediated immunotherapy for Alzheimer's disease.
    Solomon B
    Curr Opin Investig Drugs; 2007 Jul; 8(7):519-24. PubMed ID: 17659471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse.
    Seubert P; Barbour R; Khan K; Motter R; Tang P; Kholodenko D; Kling K; Schenk D; Johnson-Wood K; Schroeter S; Gill D; Jacobsen JS; Pangalos M; Basi G; Games D
    Neurodegener Dis; 2008; 5(2):65-71. PubMed ID: 18182780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism.
    Banks WA; Ortiz L; Plotkin SR; Kastin AJ
    J Pharmacol Exp Ther; 1991 Dec; 259(3):988-96. PubMed ID: 1762091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copper complexing decreases the ability of amyloid beta peptide to cross the BBB and enter brain parenchyma.
    Mare S; Penugonda S; Robinson SM; Dohgu S; Banks WA; Ercal N
    Peptides; 2007 Jul; 28(7):1424-32. PubMed ID: 17580097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.